BPC-157 (also known as PL 14736) is an oligopeptide consisting of a chain of fifteen amino acids. It has the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.[1] This peptide has a molecular formula of C62H98N16O22. The PUBCHEM ID is CID 9941957.[2]
*The peptide is banned by the World Anti-Doping Agency in 2022 under the S0 category of non-exempt substances.[3]
Pentadecapeptide BPC-157 is an intriguing peptide with potential therapeutic benefits. Commonly known as "Body Protecting Compound," is a synthetic peptide derived from a portion of a protein found in human native Gastric juice pentadecapeptide.[4] This peptide has been monitored in several clinical studies yielding incredible cytoprotective activity and is considered non-toxic.[5]
The therapeutic potential for BPC-157 has been displayed through various Preclinical Safety Assessment studies and subsequent clinical trials concerning applications for: Gastrointestinal Healing, Anti-inflammatory Effects, Neurological Benefits and Musculoskeletal Healing.
BPC-157 exhibits a diverse range of therapeutic effects across various bodily systems. It accelerates healing in gastrointestinal tissues such as the esophagus, stomach, and intestines, while also promoting recovery in Musculoskeletal structures including muscles, tendons, ligaments, and bones. Additionally, research suggests anti-inflammatory properties of BPC-157, potentially augmenting its therapeutic utility. Furthermore, there is emerging evidence pointing to its neuroprotective capabilities, which could be particularly advantageous in conditions like traumatic brain injury.[6]
Pentadecapeptide interacts with several biological processes within the human body, affecting the expression of growth factors, promoting Angiogenesis (the formation of new blood vessels), and influencing the synthesis of nitric oxide. These interactions play a crucial role in enhancing its healing properties and protective effects on various tissues and organs.[7]
Clinical trials and animal research indicate that BPC-157 may have diverse potential applications. It could significantly accelerate the wound healing process, offer protective and healing effects for stomach and intestinal ulcers, and serve as a potential treatment for Arthritis while aiding in the healing of bone fractures. Additionally, BPC-157 may provide protective and reparative benefits to various organs under stress conditions.[8]
Research
[edit]There are some tentative pre-clinical studies on animals and in vitro suggesting possible benefit in wound healing and bowel disorders although all of these studies come from a single research group.[9][10]
Unapproved marketing
[edit]BPC 157 is marketed in functional medicine, although, FDA approval is not issued yet for it to be used in standard medicine.[11]
References
[edit]- ^ Jelovac, Nikola; Sikiric, Predrag; Rucman, Rudolf; Petek, Marijan; Marovic, Anton; Perovic, Darko; Seiwerth, Sven; Mise, Stjepan; Turkovic, Branko; Dodig, Goran; Miklic, Pavle; Buljat, Gojko; Prkacin, Ingrid (1999). "Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats". European Journal of Pharmacology. 379 (1): 19–31. doi:10.1016/S0014-2999(99)00486-0. PMID 10499368.
- ^ "PUBCHEM". pubchem.ncbi.nlm.nih.gov. Retrieved 1 March 2021.
- ^ "2022 Prohibited List: SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" (PDF). World Anti-Doping Agency. WADA. Retrieved 21 February 2022.
- ^ Bjelakovic, Goran (February 20, 2008). "Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis". pubmed.ncbi.nlm.nih.gov/.
- ^ Vukojević, Jakša (August 4, 2021). "Pentadecapeptide BPC 157 and the central nervous system". www.ncbi.nlm.nih.gov/.
- ^ Chang, Chung-Hsun (October 28, 2010). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration". Journal of Applied Physiology. 110 (3) – via JAPPLPHYSIOL.
- ^ Staresinic, Mario (2003). "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth". Journal of Orthopaedic Research. 21 (6): 976–983 – via Elsevier Science Direct.
- ^ Sikiric, Predrag & Seiwerth, Sven & Rucman, Rudolf & Turkovic, Branko & Rokotov, Dinko & Brcic, Luka & Sever, Marko & Kliček, Robert & Radic, Bozo & Drmic, Domagoj & Ilic, Spomenko & Kolenc, Danijela & Vrcic, Hrvoje & Sebecic, Bozidar. (2011). Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current pharmaceutical design. 17. 1612-32. 10.2174/138161211796196954.
- ^ Sikiric, P.; Seiwerth, S.; Brcic, L.; Blagaic, A. B.; Zoricic, I.; Sever, M.; Klicek, R.; Radic, B.; Keller, N.; Sipos, K.; Jakir, A.; Udovicic, M.; Tonkic, A.; Kokic, N.; Turkovic, B.; Mise, S.; Anic, T. (2006). "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response". Inflammopharmacology. 14 (5–6): 214–21. doi:10.1007/s10787-006-1531-7. PMID 17186181. S2CID 24132425.
- ^ Cerovecki, Tomislav; Bojanic, Ivan; Brcic, Luka; Radic, Bozo; Vukoja, Ivan; Seiwerth, Sven; Sikiric, Predrag (September 2010). "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat". Journal of Orthopaedic Research. 28 (9): 1155–1161. doi:10.1002/jor.21107. ISSN 1554-527X. PMID 20225319. S2CID 22085833.
- ^ Sikiric, P; Seiwerth, S; Rucman, R; Kolenc, D; Vuletic, LB; Drmic, D; Grgic, T; Strbe, S; Zukanovic, G; Crvenkovic, D; Madzarac, G; Rukavina, I; Sucic, M; Baric, M; Starcevic, N; Krstonijevic, Z; Bencic, ML; Filipcic, I; Rokotov, DS; Vlainic, J (2016). "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications". Current Neuropharmacology. 14 (8): 857–865. doi:10.2174/1570159x13666160502153022. PMC 5333585. PMID 27138887.